GlassScriptPhysician profile
Mari-Jane Shaffer
NPI 1356718308
$3,740.23
in general payments reported to CMS, 2019-2025
21 companies · $1,614 in 2025
The $1,614 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.25 · 2022: $125 · 2023: $828 · 2024: $1,139 · 2025: $1,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,580.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $695.50 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $688.61 | 2021-2025 | Caplyta |
| Abbvie INC. | $660.26 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $515.64 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $385.00 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $299.68 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $127.21 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $78.11 | 2025 | Trintellix |
| Abbott Laboratories | $40.60 | 2022-2023 | Freestyle Libre 3 |
| Bausch Health US, LLC | $34.92 | 2023-2024 | Aplenzin, Wellbutrin |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.10 | 2025 | Rejoyn |
| Ironshore Pharmaceuticals INC. | $21.96 | 2022 | |
| Collegium Pharmaceutical, INC. | $21.90 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $20.56 | 2023 | Xelstrym |
| Alkermes, INC. | $20.38 | 2025 | Aristada, Lybalvi |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $20.01 | 2024 | Dyanavel Xr |
| Corium, LLC | $19.61 | 2022 | |
| Neurocrine Biosciences, INC. | $19.11 | 2024 | Ingrezza |
| Neos Therapeutics, LP | $17.40 | 2022 | |
| Novo Nordisk INC | $16.88 | 2021 | |
| Supernus Pharmaceuticals, INC. | $14.79 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mari-Jane Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.